Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $16.27, but opened at $16.60. Sionna Therapeutics shares last traded at $16.00, with a volume of 29,024 shares.
Analysts Set New Price Targets
A number of research firms have recently commented on SION. Stifel Nicolaus began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating and a $32.00 target price on the stock. Guggenheim began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price on the stock. Finally, TD Cowen began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating on the stock.
View Our Latest Research Report on Sionna Therapeutics
Sionna Therapeutics Trading Up 9.1 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- Best Aerospace Stocks Investing
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Best Stocks Under $10.00
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- 3 Warren Buffett Stocks to Buy Now
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
